상단메뉴 바로가기 본문 바로가기 본문 하위메뉴 바로가기 하단 바로가기
About

UCI Therapeutics

"UCI Therapeutics is a dedicated team of passionate researchers focused on developing
CAR-NK therapy for both hematologic and solid malignancies, believing that every patient deserves hope,
and our mission is to deliver innovative and effective solutions for those battling cancer."

UCI Therapeutics is a dynamic startup pioneering innovation in the field of biopharmaceuticals, with a motto of 'Designing
Innovative Biological Medicines.' Our mission is to leverage the fundamental unit of life, the cell, to address the limitations of
existing drugs and maximize their strengths by crafting biotherapeutics. The differentiated cellular approach of UCI
Therapeutics is designed to enhance and empower the unique prowess of Natural Killer (NK) cells.

Technology

Unlocking the Power of NK Cells

We are tapping the remarkable abilities of Natural Killer (NK) cells. These immune warriors possess the unique
capability to swiftly attack abnormal cells, especially evasive ones. Their ongoing surveillance and adaptive intelligence
help actively eradicate cancer. At UCI Therapeutics, we are evolving innovative therapies harnessing the potential of NK cells.
Indeed, our exclusive technology is designed to enhance the targeting functions of NK cells while maximizing their therapeutic effectiveness.

UCI Therapeutics Engineered CAR-NK cells

tech-cell-01
Bispecific CAR-NK

Bispecific CAR-NK cells are designed with two scFvs,
each capable of recognizing distinct antigens
on a single CAR.

UCI101
Targets both CD19 and CD22 &
Therapy for Diffuse Large B Cell Lymphoma
tech-cell-02
CellTaCT™ CAR-NK

CellTaCT™ Platform focuses on engineering
CAR-NK cells to pinpoint cancer cells and modulate
the tumor microenvironment.

UCI112
Targets MSLN & Secretes TGF-beta inhibitor peptides
UCI113
Targets HER2 & Secretes TGF-beta inhibitor peptides
UCI114
Targets CLDN18.2 & Secretes TGF-beta inhibitor peptides
UCI121
Targets Endoglin & Secretes CAF inhibitor peptides

UCI Therapeutics’ off-the-shelf Allogeneic Manufacturing

We recognize that cancer patients often have an inadequate immune response against the disease.
To address this challenge, we are dedicated to advancing our proprietary methods for bolstering the immune response.
Our focus lies in the development of allogeneic, off-the-shelf NK cell-based therapies.
Our innovative technology aims to overcome the limitations of the natural immune response,
offering new hope to patients battling cancer.

  1. Collect & Isolate
    Collect & Isolate
    PBMCs are isolated from
    healthy donors by
    leukapheresis.
  2. Feeder
    Active
    NK cells are expanded
    using feeder cells
    and cytokines.
  3. Nanobeads
    Enrich & Engineer
    NK cells are enriched with
    CD3 nanobeads and
    engineered to express
    the CAR.
  4. Expand
    Expand
    Continued expansion is
    performed using a
    single-use bioreactor at
    a scale of 10~40 L.
  5. Harvest
    Harvest
    Harvest and purification of
    NK cells are performed
    in aseptic conditions.
  6. Fill & Cryopreservation
    Fill & Cryopreservation
    Quality control and
    cryopreservation are
    conducted with an
    injectable formulation.
  7. Administer
    Administer
    NK product is thawed
    for off-the-shelf use
    and administered
    to patients.
Pipeline

Lead Programs

program_table

Contact

address
605, 14, Seongsui-ro 10-gil, Seongdong-gu, Seoul, Republic of Korea
tel
02-6466-3636
mail
contact@uci-therapeutics.com